In a telemedicine world where you can't palpate joints virtually, how can we use pt self-joint counts well? Patients & rheums might not always rate the same, but: when RA pts say their joints are up or down, rheum exam usually agrees👍 @earlyarthritis #ACR21 ABST1203 @RheumNow https://t.co/spUNTlMnDY

#ACR21 Abst#1205- Discordance bw pt and MD global assessment in RA? ⭐️15% discordance (>30 mm difference in GA score) ⭐️⬆️ in LDA and mod disease, ⬇️ remission/high disease ⭐️♂️ sex, pain VAS, normal CRP, less TJC&SJC predictive @Rheumnow https://t.co/N2qAaDiBE5

• https://bit.ly/31ATIQR

#ACR21 Abs#1210: Frequency of anterior atlanto-axial sublux in RA ⭐️Anterior atlanto-axial subluxation (aAAS) = 3+ mm, frequency = 25% ⭐️Radicular pain 20%, surgery 6% ▶️Longer disease duration, ⬆️ frequency of extra-articular manifestations https://t.co/BfjCTlRJbt @Rheumnow https://t.co/xd9h5e9cDH

• https://bit.ly/3GUrrF4

#clinicalpearls Cervical involvement in RA: is it underestimated? Cohort of 240pts: anterior atlantoaxial subluxation (aAAS) found in n=25 10.4 % patients, 1/3 with no neck pain! Joint restriction OR: 5.8 hx arthroplasty OR:3.6 #Abst1211 #ACR21 @RheumNow https://t.co/KRkDP4ETMu https://t.co/soKTMPiMwy

• Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in…

#RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than pts receiving biologic /other tsDMARD. 👉🏼Results from RA-BE-REAL observational study 👉🏼Bari(2 or 4mg) vs biologic/other tsDMARD Abs#1223 #ACR21 @RheumNow https://t.co/WRN1OCX9Bq https://t.co/UCFF6hAY7G

• A Multinational, Prospective, Observational Study in Patients with Rheumatoid A…

#ACR21 Abs#1224. ⬇️ CD39 expression on B cell predicts occurrence of anti-drug Ab in RA on RTX ⭐️13/23 pts on RTX became ADAb+. No diff in concomitant MTX usage ⭐️Baseline CD73 similar, but lower CD39 predictive of ADAb https://t.co/QzbAmXtTmZ @Rheumnow https://t.co/CLtEev69YD

• https://bit.ly/2YpkRVG

#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow

• https://bit.ly/31wNLV2

Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu